The Role of Donor Lymphocyte Infusion (DLI) in Post Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era

The optimal approach to patients with chronic myeloid leukemia (CML) that relapse following allogeneic hematopoietic cell transplantation (HCT) in the tyrosine kinase inhibitors (TKIs) era is unknown. Imatinib was introduced in 2001 being followed by the introduction of second generation TKIs such as dasatinib or nilotinib, in subsequent years [1,2]. In later years, the spectrum of TKIs has further broadened, given the introduction of bosutinib and ponatinib [3,4]. Nevertheless, allogeneic HCT remains an important rescue strategy for some CML patients at adverse risk.

Source: Biology of Blood and Marrow Transplantation - February 12, 2020 Category: Hematology Authors: Sarah Schmidt, Ying Liu, Zhen-Huan Hu, Kirsten M. Williams, Hillard M. Lazarus, Ravi Vij, Mohamed A. Kharfan-Dabaja, Guillermo Ort í, Peter H. Wiernik, Daniel Weisdorf, Rammurti T. Kamble, Roger Herzig, Baldeep Wirk, Jan Cerny, Ulrike Bacher, Naeem A Cha Source Type: research